Sen. Grassley Seeks FDA Documents On Vioxx Labeling Changes
This article was originally published in The Pink Sheet Daily
Executive Summary
Senate Finance Committee chair questions why FDA did not adopt recommendations by a cardio-renal division medical officer that a cardiovascular warning be added to Vioxx labeling. Grassley calls FDA’s drug safety initiative “welcome, albeit late in coming.”